Literature DB >> 19422477

Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus.

Ichiro Konishi1, Yoichi Hiasa, Syuichiro Shigematsu, Masashi Hirooka, Shinya Furukawa, Masanori Abe, Bunzo Matsuura, Kojiro Michitaka, Norio Horiike, Morikazu Onji.   

Abstract

BACKGROUND: Patients with hepatitis C virus (HCV) frequently show glucose intolerance. Diabetes mellitus (DM) has been proposed to be a risk factor for hepatocellular carcinoma (HCC). AIMS: The aim of this study is to clarify the influence of glucose intolerance as evaluated by the 75 g oral glucose tolerance test (OGTT) on hepatocarcinogenesis in patients with HCV.
METHODS: This study was carried out in a cohort of 197 patients with HCV who had not been previously diagnosed as having DM. All patients underwent the 75 g OGTT at entry. They were also screened for HCC and, thereafter, the rate of hepatocarcinogenesis was compared between the patients with and without glucose intolerance.
RESULTS: Based on the results of the 75 g OGTT, 125 (63%) had normal glucose tolerance (NGT), 49 (25%) had impaired glucose tolerance (IGT) and 23 (12%) had the DM pattern. HCC occurred more frequently in patients with the DM pattern than in patients with either NGT or IGT. Even in patients without advanced liver fibrosis, HCC was more frequently observed in patients with DM than in patients with NGT. A multiple logistic regression analysis showed advanced liver fibrosis, the DM pattern on the 75 g OGTT, an older age and gamma-glutamyltransferase to all be independent risk factors related to hepatocarcinogenesis.
CONCLUSIONS: A DM pattern on the 75 g OGTT was thus found to be associated with hepatocarcinogenesis and the 75 g OGTT is considered to be useful for identifying this risk factor for HCC in patients with HCV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422477     DOI: 10.1111/j.1478-3231.2009.02043.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

1.  Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients.

Authors:  Shaogui Wan; Hie-Won Hann; Zhong Ye; Richard S Hann; Yinzhi Lai; Chun Wang; Ling Li; Ronald E Myers; Bingshan Li; Jinliang Xing; Hushan Yang
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

2.  Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.

Authors:  Neil Mehta; Monika Sarkar; Jennifer L Dodge; Nicholas Fidelman; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2016-01-08       Impact factor: 5.799

3.  Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.

Authors:  Valter Donadon; Massimiliano Balbi; Francesca Valent; Angelo Avogaro
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

4.  Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Authors:  Tracey G Simon; Hector Bonilla; Peng Yan; Raymond T Chung; Adeel A Butt
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

5.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Hirokazu Takahashi; Toshihiko Mizuta; Yuichiro Eguchi; Yasunori Kawaguchi; Takuya Kuwashiro; Satoshi Oeda; Hiroshi Isoda; Noriko Oza; Shinji Iwane; Kenichi Izumi; Keizou Anzai; Iwata Ozaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

6.  Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.

Authors:  Tsuyoshi Ishikawa; Shogo Shiratsuki; Takashi Matsuda; Takuya Iwamoto; Taro Takami; Koichi Uchida; Shuji Terai; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2013-10-05       Impact factor: 7.527

7.  Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor Jesús Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

8.  Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence.

Authors:  Abby B Siegel; Hashem B El-Serag
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-08       Impact factor: 3.869

9.  Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review.

Authors:  Harleen K Dyal; Maria Aguilar; Gabriella Bartos; Edward W Holt; Taft Bhuket; Benny Liu; Ramsey Cheung; Robert J Wong
Journal:  Dig Dis Sci       Date:  2015-12-24       Impact factor: 3.199

10.  The functional cancer map: a systems-level synopsis of genetic deregulation in cancer.

Authors:  Markus Krupp; Thorsten Maass; Jens U Marquardt; Frank Staib; Tobias Bauer; Rainer König; Stefan Biesterfeld; Peter R Galle; Achim Tresch; Andreas Teufel
Journal:  BMC Med Genomics       Date:  2011-06-30       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.